[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

# ![@UOzkerim Avatar](https://lunarcrush.com/gi/w:26/cr:twitter::1956119871294726144.png) @UOzkerim Uğur özkerim

Uğur özkerim posts on X about live from, events, os the most. They currently have XXX followers and XX posts still getting attention that total XXX engagements in the last XX hours.

### Engagements: XXX [#](/creator/twitter::1956119871294726144/interactions)
![Engagements Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1956119871294726144/c:line/m:interactions.svg)

- X Week XXXXX +170%
- X Month XXXXXX +12,268%

### Mentions: X [#](/creator/twitter::1956119871294726144/posts_active)
![Mentions Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1956119871294726144/c:line/m:posts_active.svg)


### Followers: XXX [#](/creator/twitter::1956119871294726144/followers)
![Followers Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1956119871294726144/c:line/m:followers.svg)

- X Week XXX +8.50%
- X Month XXX +48%

### CreatorRank: XXXXXXXXX [#](/creator/twitter::1956119871294726144/influencer_rank)
![CreatorRank Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1956119871294726144/c:line/m:influencer_rank.svg)

### Social Influence [#](/creator/twitter::1956119871294726144/influence)
---

**Social topic influence**
[live from](/topic/live-from), [events](/topic/events), [os](/topic/os)
### Top Social Posts [#](/creator/twitter::1956119871294726144/posts)
---
Top posts by engagements in the last XX hours

"🚨 DESTINY-Breast11 delivers the highest pCR ever reported in neoadjuvant HER2+ early breast cancer 💥 T-DXd + THP achieved XXXX % pCR vs XXXX % with ddAC-THP ( XXXX % p = 0.003) ⚡ Early EFS trend also favors T-DXd ( HR XXXX ) 🫁 Fewer Grade X AEs and low ILD rates a potential new standard emerges. #ESMO25 #BreastCancer #HER2 #TDXd @OncoAlert"  
[X Link](https://x.com/UOzkerim/status/1979558616697913720) [@UOzkerim](/creator/x/UOzkerim) 2025-10-18T14:42Z XXX followers, XXX engagements


"🔥 #ESMO25 TROPION-Breast02 After Sacituzumab govitecan now Datopotamab deruxtecan (Dato-DXd) takes the stage another ADC rewriting the treatment landscape of metastatic TNBC 💥 In patients not eligible for immunotherapy: ✅ PFS HR XXXX (p 0.0001) median XXXX vs XXX mo ✅ OS HR XXXX (p = 0.029) median XXXX vs XXXX mo ✅ Benefit consistent across all subgroups Dato-DXd achieved dual gains in PFS and OS the first new 1L option in over a decade for this challenging TNBC population. ADC era in TNBC is clearly here to stay. 🧬 @OncoAlert @MedwatchKate @OncoReporte #ESMO25 #TNBC #BreastCancer #DatoDXd"  
[X Link](https://x.com/UOzkerim/status/1979833952329154743) [@UOzkerim](/creator/x/UOzkerim) 2025-10-19T08:56Z XXX followers, 2784 engagements


"🚀 The #ESMO25 data keep coming In 1L sq-NSCLC the HARMONi-6 trial showed that Ivonescimab + chemo delivered a clear PFS win over Tislelizumab + chemo. 🕒 XXXX vs XXX mo (HR XXXX p0.0001) Benefit consistent across all PD-L1 subgroups. 🧬 Manageable safety a promising step toward a new standard of care. Will HARMONi-6 redefine first-line therapy in sq-NSCLC 💭 #LungCancer #NSCLC #Immunotherapy #ESMO25 @OncoAlert @myESMO @YoungLungCancer @_SEOM @Lung_Cancers @LungSummit @OncoReporte @MedwatchKate"  
[X Link](https://x.com/UOzkerim/status/1979921913838285287) [@UOzkerim](/creator/x/UOzkerim) 2025-10-19T14:45Z XXX followers, 1276 engagements


"🚀 LIVE from #ESMO25 Berlin The SOHO-01 trial unveils Sevabertinib (BAY 2927088) for HER2-mutant NSCLC showing robust & durable responses across cohorts: ORR 6471% (BICR) Manageable safety (mostly diarrhea no ILD or pneumonitis) Activity seen in both pretreated and 1L settings 👏 A new potential standard emerging for HER2-mutant NSCLC @OncoAlert #LungCancer #HER2 #NSCLC #ESMO25"  
[X Link](https://x.com/UOzkerim/status/1979196280468377739) [@UOzkerim](/creator/x/UOzkerim) 2025-10-17T14:42Z XXX followers, XXX engagements


"❌ Negative trial alert at #ESMO25 Berlin TRIPLET-HCC (PRODIGE XX / FFCD 2101): Adding low-dose Ipilimumab (1 mg/kg 4) to Atezolizumab + Bevacizumab in 1L unresectable HCC failed to improve efficacy. 📉 ORR XX % vs XX % 🕒 Median PFS XX mo (similar) 💊 Tolerability slightly better with Atezo/Bev ⚠ X grade X events in triplet arm Low-dose Ipi didnt add benefit higher-dose schedules (3 mg/kg) may still hold potential. @OncoAlert"  
[X Link](https://x.com/UOzkerim/status/1979480076581298563) [@UOzkerim](/creator/x/UOzkerim) 2025-10-18T09:30Z XXX followers, XXX engagements


"🔥 #ESMO25 KEYNOTE-905 / EV-303 In cisplatin-ineligible muscle-invasive bladder cancer (MIBC) Enfortumab vedotin + Pembrolizumab delivers practice-changing results 💥 ✅ pCR XX% vs X% ✅ EFS HR XXXX (p 0.0001) ✅ OS HR XXXX (p = 0.0002) A chemo-free regimen showing dual benefit in both pathological response and survival EV + pembro is poised to redefine the pre-surgical standard of care in MIBC. @OncoAlert @weoncologists #OncoAlert #ESMO25 #BladderCancer"  
[X Link](https://x.com/UOzkerim/status/1979574570471612503) [@UOzkerim](/creator/x/UOzkerim) 2025-10-18T15:45Z XXX followers, XXX engagements


"🚫 The phase III PAULIEN trial in 1L PD-L1 XX% NSCLC showed no added benefit from combining chemotherapy with pembrolizumab. No improvement in response PFS or OS just higher toxicity. Sometimes immunotherapy alone is enough. 💬 Do you think thats enough for these patients #ESMO25 @OncoAlert @brunolarvol @OncoReporte @Lung_Cancers @MedwatchKate"  
[X Link](https://x.com/UOzkerim/status/1980242654584619270) [@UOzkerim](/creator/x/UOzkerim) 2025-10-20T12:00Z XXX followers, 1199 engagements


"🔥 #ESMO25 Breaking ALINA trial update With nearly X years of follow-up adjuvant alectinib continues to show a sustained clinically meaningful DFS benefit over chemotherapy in resected ALK+ NSCLC (HR 0.350.40). CNS-DFS also favored alectinib and OS trend remains positive 💪 @OncoAlert @weoncologists @MedwatchKate @OncoReporte @_SEOM @Lung_Cancers"  
[X Link](https://x.com/UOzkerim/status/1980257460637118621) [@UOzkerim](/creator/x/UOzkerim) 2025-10-20T12:59Z XXX followers, 1687 engagements


"#ESMO25 ALK+ NSCLC: Adjuvant era update Both ALINA and ELEVATE trials strengthen the role of adjuvant ALK inhibition after resection: #ALINA: With X years of follow-up alectinib maintains durable DFS & CNS-DFS benefit vs chemo confirming its SoC position. #ELEVATE: Ensartinib shows significant DFS improvement in stage IIIIIB (HR 0.20) consistent across subgroups. The ALK story in early-stage NSCLC keeps evolving 🔬 @OncoAlert @weoncologists @MedwatchKate @OncoReporte @_SEOM"  
[X Link](https://x.com/UOzkerim/status/1980263604076085414) [@UOzkerim](/creator/x/UOzkerim) 2025-10-20T13:23Z XXX followers, 1006 engagements


"🧬 #ESMO25 BR.31 trial update Adjuvant durvalumab in early-stage NSCLC did not improve OS or DFS in the overall PD-L1 XX% EGFR/ALK population. However MRD analysis brought key insights: MRD positivity (10%) was highly prognostic for poor OS. In exploratory analysis durvalumab significantly improved OS in MRD-positive patients regardless of PD-L1 level. These findings highlight MRD as a potential biomarker guiding adjuvant immunotherapy decisions in resected NSCLC @OncoAlert @OncoReporte @MedwatchKate @_SEOM"  
[X Link](https://x.com/UOzkerim/status/1980266602328211825) [@UOzkerim](/creator/x/UOzkerim) 2025-10-20T13:35Z XXX followers, XXX engagements


"#ESMO25 LungMate-013 Trial Induction serplulimab + chemotherapy followed by surgery vs radiotherapy in initially unresectable stage IIIBIIIC NSCLC. 🔹 Patients converted to resectable disease and undergoing surgery achieved better EFS (HR 0.38; XX% CI 0.141.01). 🔹 Median EFS XXXX months overall. 🔹 However experts raised an important point was radiotherapy alone the right comparator Concurrent chemoradiation is the standard backbone so results should be interpreted with caution. Still the trial brings renewed attention to the potential role of conversion surgery after effective induction"  
[X Link](https://x.com/UOzkerim/status/1980268554185257128) [@UOzkerim](/creator/x/UOzkerim) 2025-10-20T13:43Z XXX followers, XXX engagements

[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

@UOzkerim Uğur özkerim

Uğur özkerim posts on X about live from, events, os the most. They currently have XXX followers and XX posts still getting attention that total XXX engagements in the last XX hours.

Engagements: XXX #

X Week XXXXX +170%
X Month XXXXXX +12,268%

Mentions: X #

Followers: XXX #

X Week XXX +8.50%
X Month XXX +48%

CreatorRank: XXXXXXXXX #

Social Influence #

Social topic influence live from, events, os

Top Social Posts #

Top posts by engagements in the last XX hours

"🚨 DESTINY-Breast11 delivers the highest pCR ever reported in neoadjuvant HER2+ early breast cancer 💥 T-DXd + THP achieved XXXX % pCR vs XXXX % with ddAC-THP ( XXXX % p = 0.003) ⚡ Early EFS trend also favors T-DXd ( HR XXXX ) 🫁 Fewer Grade X AEs and low ILD rates a potential new standard emerges. #ESMO25 #BreastCancer #HER2 #TDXd @OncoAlert"
X Link @UOzkerim 2025-10-18T14:42Z XXX followers, XXX engagements

"🔥 #ESMO25 TROPION-Breast02 After Sacituzumab govitecan now Datopotamab deruxtecan (Dato-DXd) takes the stage another ADC rewriting the treatment landscape of metastatic TNBC 💥 In patients not eligible for immunotherapy: ✅ PFS HR XXXX (p 0.0001) median XXXX vs XXX mo ✅ OS HR XXXX (p = 0.029) median XXXX vs XXXX mo ✅ Benefit consistent across all subgroups Dato-DXd achieved dual gains in PFS and OS the first new 1L option in over a decade for this challenging TNBC population. ADC era in TNBC is clearly here to stay. 🧬 @OncoAlert @MedwatchKate @OncoReporte #ESMO25 #TNBC #BreastCancer #DatoDXd"
X Link @UOzkerim 2025-10-19T08:56Z XXX followers, 2784 engagements

"🚀 The #ESMO25 data keep coming In 1L sq-NSCLC the HARMONi-6 trial showed that Ivonescimab + chemo delivered a clear PFS win over Tislelizumab + chemo. 🕒 XXXX vs XXX mo (HR XXXX p0.0001) Benefit consistent across all PD-L1 subgroups. 🧬 Manageable safety a promising step toward a new standard of care. Will HARMONi-6 redefine first-line therapy in sq-NSCLC 💭 #LungCancer #NSCLC #Immunotherapy #ESMO25 @OncoAlert @myESMO @YoungLungCancer @_SEOM @Lung_Cancers @LungSummit @OncoReporte @MedwatchKate"
X Link @UOzkerim 2025-10-19T14:45Z XXX followers, 1276 engagements

"🚀 LIVE from #ESMO25 Berlin The SOHO-01 trial unveils Sevabertinib (BAY 2927088) for HER2-mutant NSCLC showing robust & durable responses across cohorts: ORR 6471% (BICR) Manageable safety (mostly diarrhea no ILD or pneumonitis) Activity seen in both pretreated and 1L settings 👏 A new potential standard emerging for HER2-mutant NSCLC @OncoAlert #LungCancer #HER2 #NSCLC #ESMO25"
X Link @UOzkerim 2025-10-17T14:42Z XXX followers, XXX engagements

"❌ Negative trial alert at #ESMO25 Berlin TRIPLET-HCC (PRODIGE XX / FFCD 2101): Adding low-dose Ipilimumab (1 mg/kg 4) to Atezolizumab + Bevacizumab in 1L unresectable HCC failed to improve efficacy. 📉 ORR XX % vs XX % 🕒 Median PFS XX mo (similar) 💊 Tolerability slightly better with Atezo/Bev ⚠ X grade X events in triplet arm Low-dose Ipi didnt add benefit higher-dose schedules (3 mg/kg) may still hold potential. @OncoAlert"
X Link @UOzkerim 2025-10-18T09:30Z XXX followers, XXX engagements

"🔥 #ESMO25 KEYNOTE-905 / EV-303 In cisplatin-ineligible muscle-invasive bladder cancer (MIBC) Enfortumab vedotin + Pembrolizumab delivers practice-changing results 💥 ✅ pCR XX% vs X% ✅ EFS HR XXXX (p 0.0001) ✅ OS HR XXXX (p = 0.0002) A chemo-free regimen showing dual benefit in both pathological response and survival EV + pembro is poised to redefine the pre-surgical standard of care in MIBC. @OncoAlert @weoncologists #OncoAlert #ESMO25 #BladderCancer"
X Link @UOzkerim 2025-10-18T15:45Z XXX followers, XXX engagements

"🚫 The phase III PAULIEN trial in 1L PD-L1 XX% NSCLC showed no added benefit from combining chemotherapy with pembrolizumab. No improvement in response PFS or OS just higher toxicity. Sometimes immunotherapy alone is enough. 💬 Do you think thats enough for these patients #ESMO25 @OncoAlert @brunolarvol @OncoReporte @Lung_Cancers @MedwatchKate"
X Link @UOzkerim 2025-10-20T12:00Z XXX followers, 1199 engagements

"🔥 #ESMO25 Breaking ALINA trial update With nearly X years of follow-up adjuvant alectinib continues to show a sustained clinically meaningful DFS benefit over chemotherapy in resected ALK+ NSCLC (HR 0.350.40). CNS-DFS also favored alectinib and OS trend remains positive 💪 @OncoAlert @weoncologists @MedwatchKate @OncoReporte @_SEOM @Lung_Cancers"
X Link @UOzkerim 2025-10-20T12:59Z XXX followers, 1687 engagements

"#ESMO25 ALK+ NSCLC: Adjuvant era update Both ALINA and ELEVATE trials strengthen the role of adjuvant ALK inhibition after resection: #ALINA: With X years of follow-up alectinib maintains durable DFS & CNS-DFS benefit vs chemo confirming its SoC position. #ELEVATE: Ensartinib shows significant DFS improvement in stage IIIIIB (HR 0.20) consistent across subgroups. The ALK story in early-stage NSCLC keeps evolving 🔬 @OncoAlert @weoncologists @MedwatchKate @OncoReporte @_SEOM"
X Link @UOzkerim 2025-10-20T13:23Z XXX followers, 1006 engagements

"🧬 #ESMO25 BR.31 trial update Adjuvant durvalumab in early-stage NSCLC did not improve OS or DFS in the overall PD-L1 XX% EGFR/ALK population. However MRD analysis brought key insights: MRD positivity (10%) was highly prognostic for poor OS. In exploratory analysis durvalumab significantly improved OS in MRD-positive patients regardless of PD-L1 level. These findings highlight MRD as a potential biomarker guiding adjuvant immunotherapy decisions in resected NSCLC @OncoAlert @OncoReporte @MedwatchKate @_SEOM"
X Link @UOzkerim 2025-10-20T13:35Z XXX followers, XXX engagements

"#ESMO25 LungMate-013 Trial Induction serplulimab + chemotherapy followed by surgery vs radiotherapy in initially unresectable stage IIIBIIIC NSCLC. 🔹 Patients converted to resectable disease and undergoing surgery achieved better EFS (HR 0.38; XX% CI 0.141.01). 🔹 Median EFS XXXX months overall. 🔹 However experts raised an important point was radiotherapy alone the right comparator Concurrent chemoradiation is the standard backbone so results should be interpreted with caution. Still the trial brings renewed attention to the potential role of conversion surgery after effective induction"
X Link @UOzkerim 2025-10-20T13:43Z XXX followers, XXX engagements